In patients with osteoporosis, discontinuation of long-term drug administration is an important issue in therapy. To investigate this problem, in 9 pharmacies in Toyama, we asked patients who were taking a new type of Alendronate drug, Alendronate Sodium oral jelly (Bonalon® Oral Jelly), about their feelings.
Their feelings were evaluated according to a 5-grade system (1: bad to 5: good) and analyzed by customer satisfaction analysis. The mean of comprehensive impression, indicating the degree of satisfaction, was 3.94. Ease of swallowing, ease of taking out from package, and softness of jelly influenced a good impression. On the other hand, the size of jelly had a negative correlation with comprehensive impression.
In patients requiring long-term care, using a nauseous medicine and a medicine that is difficult to take from the package induces non-compliance with the drug-taking regime. The new oral jelly was rated as having a good impression in the feeling of use. This result indicates that using this jelly might help to reduce non-compliance in long-term drug administration in osteoporosis patients.